ACUTE RECOIL FOLLOWING IMPLANTATION OF EVEROLIMUS-ELUTING ABSORB BIODEGRADABLE VASCULAR SCAFFOLDS OR XIENCE METALLIC STENTS: THE ABSORB II TRIAL

Bernard Chevalier; Yuki Ishibashi; Yoshinobu Onuma; Patrick W. Serruys

doi:10.1016/s0735-1097(15)61930-1

Related publications

Article2016

Acute Gain in Minimal Lumen Area Following Implantation of Everolimus-Eluting ABSORB Biodegradable Vascular Scaffolds or Xience Metallic Stents

Yohei Sotomi, Yuki Ishibashi, Pannipa Suwannasom, Shimpei Nakatani, Yun‐Kyeong Cho, Maik J. Grundeken, Yaping Zeng, Hiroki Tateishi, Pieter C. Smits, Paul Barragan, Ran Kornowski, Anthony Gershlick, Stephan Windecker, Robert‐Jan van Geuns, Antonio L. Bartorelli, Robbert J. de Winter, Jan Tijssen, Patrick W. Serruys, Yoshinobu Onuma

КАРДИОЛОГИЯ УЗБЕКИСТАНА

Article2020

Bioresorbable scaffolds versus everolimus-eluting metallic stents: five-year clinical outcomes of the randomised ABSORB II trial

Yoshinobu Onuma, Bernard Chevalier, Masafumi Ono, Ángel Cequier, Dariusz Dudek, Michael Haude, Didier Carrié, Manel Sabaté, Stephan Windecker, Richard Rapoza, Nick E.J. West, Sebastian Reith, Manuel de Sousa Almeida, Gianluca Campo, Andrés Íñiguez, Patrick W. Serruys

EuroIntervention

Article2016

TCT-415 Absorb Bioresorbable Vascular Scaffolds vs. XIENCE Everolimus-Eluting Stents: Are Clinical Outcomes Different for Men and Women?

Dean J. Kereiakes, Stephen G. Ellis, Runlin Gao, Takeshi Kimura, Yoshinobu Onuma, Karine Piard‐Ruster, Yunlong Zhang, Kai Koo, Patrick W. Serruys, Gregg W. Stone

Journal of the American College of Cardiology

Article2015

DIFFERENCES IN THE OCCURRENCE OF NEW OR WORSENING ANGINA BETWEEN THE ABSORB BIORESORBABLE VASCULAR SCAFFOLD AND XIENCE METALLIC STENT: A POST-HOC ANALYSIS OF THE ABSORB II RANDOMIZED TRIAL

Bernard Chevalier, Maik J. Grundeken, Roseann White, Yuki Ishibashi, Héctor García García, Yoshinobu Onuma, Patrick W. Serruys

Journal of the American College of Cardiology

Article2018

TCT-62 Five-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Scaffolds: Results From the Randomized ABSORB II Trial

Patrick W. Serruys, Bernard Chevalier

Journal of the American College of Cardiology

ACUTE RECOIL FOLLOWING IMPLANTATION OF EVEROLIMUS-ELUTING ABSORB BIODEGRADABLE VASCULAR SCAFFOLDS OR XIENCE METALLIC STENTS: THE ABSORB II TRIAL

Abstract

Discussion(0)

Related publications

Acute Gain in Minimal Lumen Area Following Implantation of Everolimus-Eluting ABSORB Biodegradable Vascular Scaffolds or Xience Metallic Stents

Bioresorbable scaffolds versus everolimus-eluting metallic stents: five-year clinical outcomes of the randomised ABSORB II trial

TCT-415 Absorb Bioresorbable Vascular Scaffolds vs. XIENCE Everolimus-Eluting Stents: Are Clinical Outcomes Different for Men and Women?

DIFFERENCES IN THE OCCURRENCE OF NEW OR WORSENING ANGINA BETWEEN THE ABSORB BIORESORBABLE VASCULAR SCAFFOLD AND XIENCE METALLIC STENT: A POST-HOC ANALYSIS OF THE ABSORB II RANDOMIZED TRIAL

TCT-62 Five-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Scaffolds: Results From the Randomized ABSORB II Trial